Literature DB >> 31462106

Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease.

Vittoria Cicaloni1,2, Ottavia Spiga1, Giovanna Maria Dimitri3, Rebecca Maiocchi1,2, Lia Millucci1, Daniela Giustarini1, Giulia Bernardini1, Andrea Bernini1, Barbara Marzocchi1,4, Daniela Braconi1, Annalisa Santucci1.   

Abstract

Alkaptonuria (AKU) is an ultrarare autosomal recessive disorder (MIM 203500) that is caused byby a complex set of mutations in homogentisate 1,2-dioxygenasegene and consequent accumulation of homogentisic acid (HGA), causing a significant protein oxidation. A secondary form of amyloidosis was identified in AKU and related to high circulating serum amyloid A (SAA) levels, which are linked with inflammation and oxidative stress and might contribute to disease progression and patients' poor quality of life. Recently, we reported that inflammatory markers (SAA and chitotriosidase) and oxidative stress markers (protein thiolation index) might be disease activity markers in AKU. Thanks to an international network, we collected genotypic, phenotypic, and clinical data from more than 200 patients with AKU. These data are currently stored in our AKU database, named ApreciseKUre. In this work, we developed an algorithm able to make predictions about the oxidative status trend of each patient with AKU based on 55 predictors, namely circulating HGA, body mass index, total cholesterol, SAA, and chitotriosidase. Our general aim is to integrate the data of apparently heterogeneous patients with AKUAKU by using specific bioinformatics tools, in order to identify pivotal mechanisms involved in AKU for a preventive, predictive, and personalized medicine approach to AKU.-Cicaloni, V., Spiga, O., Dimitri, G. M., Maiocchi, R., Millucci, L., Giustarini, D., Bernardini, G., Bernini, A., Marzocchi, B., Braconi, D., Santucci, A. Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease.

Entities:  

Keywords:  biomarkers; machine learning; precision medicine

Mesh:

Year:  2019        PMID: 31462106      PMCID: PMC6902683          DOI: 10.1096/fj.201901529R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  55 in total

1.  Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.

Authors:  Laura Tinti; Adriano Spreafico; Daniela Braconi; Lia Millucci; Giulia Bernardini; Federico Chellini; Giovanni Cavallo; Enrico Selvi; Mauro Galeazzi; Roberto Marcolongo; James A Gallagher; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre project.

Authors:  D Braconi; D Giustarini; B Marzocchi; L Peruzzi; M Margollicci; R Rossi; G Bernardini; L Millucci; J A Gallagher; K-H Le Quan Sang; R Imrich; J Rovensky; M Al-Sbou; L R Ranganath; A Santucci
Journal:  Osteoarthritis Cartilage       Date:  2018-05-29       Impact factor: 6.576

3.  Comparative proteomics in alkaptonuria provides insights into inflammation and oxidative stress.

Authors:  Daniela Braconi; Giulia Bernardini; Alessandro Paffetti; Lia Millucci; Michela Geminiani; Marcella Laschi; Bruno Frediani; Barbara Marzocchi; Annalisa Santucci
Journal:  Int J Biochem Cell Biol       Date:  2016-08-31       Impact factor: 5.085

4.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.

Authors:  J D Gillmore; L B Lovat; M R Persey; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

5.  Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria.

Authors:  Thierry Vilboux; Michael Kayser; Wendy Introne; Pim Suwannarat; Isa Bernardini; Roxanne Fischer; Kevin O'Brien; Robert Kleta; Marjan Huizing; William A Gahl
Journal:  Hum Mutat       Date:  2009-12       Impact factor: 4.878

Review 6.  Alkaptonuria.

Authors:  Jemma B Mistry; Marwan Bukhari; Adam M Taylor
Journal:  Rare Dis       Date:  2013-12-18

7.  Diagnosis of secondary amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Lorenzo Ghezzi; Giulia Bernardini; Daniela Braconi; Pietro Lupetti; Federico Perfetto; Maurizio Orlandini; Annalisa Santucci
Journal:  Diagn Pathol       Date:  2014-09-26       Impact factor: 2.644

8.  Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis.

Authors:  Luca Cantarini; Teresa Giani; Antonella Fioravanti; Francesca Iacoponi; Gabriele Simonini; Ilaria Pagnini; Adriano Spreafico; Federico Chellini; Mauro Galeazzi; Rolando Cimaz
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

9.  Increasing Oxidative Stress with Progressive Hyperlipidemia in Human: Relation between Malondialdehyde and Atherogenic Index.

Authors:  Rui-Li Yang; Yong-Hui Shi; Gang Hao; Wu Li; Guo-Wei Le
Journal:  J Clin Biochem Nutr       Date:  2008-10-31       Impact factor: 3.114

10.  Alkaptonuria is a novel human secondary amyloidogenic disease.

Authors:  Lia Millucci; Adriano Spreafico; Laura Tinti; Daniela Braconi; Lorenzo Ghezzi; Eugenio Paccagnini; Giulia Bernardini; Loredana Amato; Marcella Laschi; Enrico Selvi; Mauro Galeazzi; Alessandro Mannoni; Maurizio Benucci; Pietro Lupetti; Federico Chellini; Maurizio Orlandini; Annalisa Santucci
Journal:  Biochim Biophys Acta       Date:  2012-07-28
View more
  4 in total

1.  Machine learning application for development of a data-driven predictive model able to investigate quality of life scores in a rare disease.

Authors:  Ottavia Spiga; Vittoria Cicaloni; Cosimo Fiorini; Alfonso Trezza; Anna Visibelli; Lia Millucci; Giulia Bernardini; Andrea Bernini; Barbara Marzocchi; Daniela Braconi; Filippo Prischi; Annalisa Santucci
Journal:  Orphanet J Rare Dis       Date:  2020-02-12       Impact factor: 4.123

2.  Towards a Precision Medicine Approach Based on Machine Learning for Tailoring Medical Treatment in Alkaptonuria.

Authors:  Ottavia Spiga; Vittoria Cicaloni; Anna Visibelli; Alessandro Davoli; Maria Ausilia Paparo; Maurizio Orlandini; Barbara Vecchi; Annalisa Santucci
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

3.  A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.

Authors:  Andrea Bernini; Elena Petricci; Andrea Atrei; Maria Camilla Baratto; Fabrizio Manetti; Annalisa Santucci
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

4.  HGDiscovery: An online tool providing functional and phenotypic information on novel variants of homogentisate 1,2- dioxigenase.

Authors:  Malancha Karmakar; Vittoria Cicaloni; Carlos H M Rodrigues; Ottavia Spiga; Annalisa Santucci; David B Ascher
Journal:  Curr Res Struct Biol       Date:  2022-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.